P-gp/BCRP-IN-1

P-gp/BCRP-IN-1 (compound 19) (0-200 μM, 48 h) has a weak anti-proliferative activity against A549 cells, and shows low cytotoxicity to the K562 , K562/A02, MDCK-II, MDCK-II-BCRP cells^[1].
P-gp/BCRP-IN-1 (48 h) exhibits the great reversal effect of resistance to both ADM (Adriamycin) and MX (Mitoxantrone) in K562/A02 cells and MDCK-II-BCRP cells, and increases the reversal activity of ADM (0-5 μM) and MX (0-20 μM) in a concentration-dependent manner^[1].
P-gp/BCRP-IN-1 (0-5 μM, 4 h) increases drug accumulation and prevents efflux of P-gp and BCRP^[1].
P-gp/BCRP-IN-1 (0-5 μM, 48 h) dose not affect the expression of P-gp as well as BCRP protein^[1].
P-gp/BCRP-IN-1 (0-200 μM, 4 h) decreases the viability of Caco-2 cells, inhibits the intestinal P-gp-mediated efflux of PTX and increases its concentration in the intestinal cells, can enhance the absorption and bioavailability^[1].
P-gp/BCRP-IN-1 prevents intracellular accumulation of anti-neoplastic drugs by impairing the function of P-gp and BCRP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.